Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi‐Ethnic Study of Atherosclerosis

Benson, Eve Marie; Tibuakuu, Martin; Zhao, Di; Akinkuolie, Akintunde O.; Otvos, James D.; Duprez, Daniel; Jacobs, David R.; Mora, Samia; Michos, Erin D.

doi:10.1002/clc.23069

Cited by 23 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(OR = 1.79, 95% CI = [1.48, 2.18], P = 3.79 × 10 −9 ), which was consistent with a previous follow-up study 20. This positive association was further validated when the model was further adjusted for covariates (OR = 1.86, 95% CI = [1.54, 2.32], P = 2.91 × 10 −9 ).…”

supporting

confidence: 86%

See 1 more Smart Citation

Plasma metabolites mediate the effect of HbA1c on incident cardiovascular disease

Dong

Fan

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Background We aim to discover whether HbA1c affects incident cardiovascular disease (CVD) through regulating endogenous metabolites. Methods and Results Totally, 2019 plasma samples were analyzed by liquid chromatography‐quadrupole time‐of‐flight mass spectrometry. Logistic regression and linear regression were used to screen metabolites which were associated with both CVD and HbA1c. The VanderWeele's mediation approach was performed to assess the direct effect and indirect effect (IE) in the counterfactual model. Forty‐eight metabolites showed an association with both HbA1c and CVD risk. Forty‐four of the 48 metabolites worked as mediators mediated in HbA1c's effect on CVD (odds ratio [OR]IE from 0.997 to 6.098, false discovery rate q < 0.05, mediated proportion from 0.4% to 85.4%). Pathway enrichment analysis indicated that different metabolic pathway showed significant IE (butanoate metabolism ORIE = 1.058, mediated proportion = 16.0%; alanine, aspartate and glutamate metabolism ORIE = 1.082, mediated proportion = 21.8%; TCA (citric acid) cycle metabolism ORIE = 1.048, mediated proportion = 13.8%; phenylalanine metabolism ORIE = 1.067, mediated proportion = 18.4%; glycerophospholipid metabolism ORIE = 3.007, mediated proportion = 82.2%; all the P < .01). Conclusions Our findings suggest that metabolites mediate the effect of HbA1c on incident CVD and provide a new study sight into pathogenesis of CVD.

show abstract

supporting

confidence: 86%

“…As previous reported, metabolic biomarkers always play a critical role in CVD. 20 Hyperglycemia, as measured by HbA1c level, is confirmed as an independent risk factor for CVD, and leads to a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Plasma metabolites mediate the effect of HbA1c on incident cardiovascular disease

Dong

Fan

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…LS7 scores were categorized into CVH groups classified as "optimal" (12-14, "average" (8-11), or "inadequate" (0-7). GlycA was independently inversely associated with continuous LS7 scores [176].…”

Section: Apparently Healthy Populationsmentioning

confidence: 91%

“…GlycA has been measured in apparently healthy individuals from large population studies such as WHS, 'Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin' (JUPITER) trial, and MESA. In all of them, elevated baseline circulating glycoprotein N-acetyl methyl groups were associated with longitudinal risk of CVD incidence and mortality, among other pathologies such as chronic inflammatory-related severe hospitalization, cancer, or death [106,108,175,176]. Considering the results, the authors defend GlycA's role as an important predictor of 5 to 15-year risk of CVD [107,108].…”

Section: Apparently Healthy Populationsmentioning

confidence: 94%

Title: Human Serum/Plasma Glycoprotein Analysis by 1H-NMR, an Emerging Method of Inflammatory Assessment

Fuertes-Martín

Correig

Vallvé

et al. 2020

JCM

View full text Add to dashboard Cite

Several studies suggest that variations in the concentration of plasma glycoproteins can influence cellular changes in a large number of diseases. In recent years, proton nuclear magnetic resonance (1H-NMR) has played a major role as an analytical tool for serum and plasma samples. In recent years, there is an increasing interest in the characterization of glycoproteins through 1H-NMR in order to search for reliable and robust biomarkers of disease. The objective of this review was to examine the existing studies in the literature related to the study of glycoproteins from an analytical and clinical point of view. There are currently several techniques to characterize circulating glycoproteins in serum or plasma, but in this review, we focus on 1H-NMR due to its great robustness and recent interest in its translation to the clinical setting. In fact, there is already a marker in H-NMR representing the acetyl groups of the glycoproteins, GlycA, which has been increasingly studied in clinical studies. A broad search of the literature was performed showing a general consensus that GlycA is a robust marker of systemic inflammation. The results also suggested that GlycA better captures systemic inflammation even more than C-reactive protein (CRP), a widely used classical inflammatory marker. The applications reviewed here demonstrated that GlycA was potentially a key biomarker in a wide range of diseases such as cancer, metabolic diseases, cardiovascular risk, and chronic inflammatory diseases among others. The profiling of glycoproteins through 1H-NMR launches an encouraging new paradigm for its future incorporation in clinical diagnosis.

show abstract

“…Cardiovascular and cardiometabolic mortalities were associated with arabinogalactan protein 1 (AGP1), C-type lectin domain family 3 member B (CLEC3B; tetranectin), cystatin-C, kallikrein B1 (KLKB1), insulin-like growth factor 1, N-terminal pro-b-type natriuretic peptide, peripheral myelin protein 2 (PMP2), soluble receptor for advanced glycation end products (sRAGE), and uncarboxylated matrix Gla protein (UCMGP) (168). Studies in a multi-ethnic cohort revealed a positive association between glycosylated acute phase protein (GlycA: a novel biomarker of systemic inflammation) and suboptimal cardiovascular health (169). Study results indicated that GlycA, derived from glycosylation of major acute inflammatory proteins and a stable biomarker of systemic inflammation compared to other markers (167,170) could be deployed for biomonitoring populations that have different lifestyles (dietary preferences, smoking etc.)…”

Section: Proteomicsmentioning

confidence: 99%

Use of an Exposome Approach to Understand the Effects of Exposures From the Natural, Built, and Social Environments on Cardio-Vascular Disease Onset, Progression, and Outcomes

Juárez

Hood

Song

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

Obesity, diabetes, and hypertension have increased by epidemic proportions in recent years among African Americans in comparison to Whites resulting in significant adverse cardiovascular disease (CVD) disparities. Today, African Americans are 30% more likely to die of heart disease than Whites and twice as likely to have a stroke. The causes of these disparities are not yet well-understood. Improved methods for identifying underlying risk factors is a critical first step toward reducing Black:White CVD disparities. This article will focus on environmental exposures in the external environment and how they can lead to changes at the cellular, molecular, and organ level to increase the personal risk for CVD and lead to population level CVD racial disparities. The external environment is defined in three broad domains: natural (air, water, land), built (places you live, work, and play) and social (social, demographic, economic, and political). We will describe how environmental exposures in the natural, built, and social environments "get under the skin" to affect gene expression though epigenetic, pan-omics, and related mechanisms that lead to increased risk for adverse CVD health outcomes and population level disparities. We also will examine the important role of metabolomics, proteomics, transcriptomics, genomics, and epigenomics in understanding how exposures in the natural, built, and social environments lead to CVD disparities with implications for clinical, public health, and policy interventions. In this review, we apply an exposome approach to Black:White CVD racial disparities. The exposome is a measure of all the exposures of an individual across the life course and the relationship of those exposures to health effects. The exposome represents the totality of exogenous (external) and endogenous (internal) exposures from conception onwards, simultaneously distinguishing, characterizing, and quantifying etiologic, mediating, moderating, and co-occurring risk and protective factors and their relationship to disease. Specifically, it assesses the biological mechanisms and underlying pathways through which chemical and non-chemical environmental Juarez et al. The Exposome and Cardiovascular Disease exposures are associated with CVD onset, progression and outcomes. The exposome is a promising approach for understanding the complex relationships among environment, behavior, biology, genetics, and disease phenotypes that underlie population level, Black: White CVD disparities.

show abstract

Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi‐Ethnic Study of Atherosclerosis

Cited by 23 publications

References 26 publications

Plasma metabolites mediate the effect of HbA1c on incident cardiovascular disease

Plasma metabolites mediate the effect of HbA1c on incident cardiovascular disease

Title: Human Serum/Plasma Glycoprotein Analysis by 1H-NMR, an Emerging Method of Inflammatory Assessment

Use of an Exposome Approach to Understand the Effects of Exposures From the Natural, Built, and Social Environments on Cardio-Vascular Disease Onset, Progression, and Outcomes

Contact Info

Product

Resources

About